Comparison
Sermorelin vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
86168-78-7
2179963-22-7
Molecular weight
3358 g/mol
4727 g/mol
Half-life
0.2 h
168 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSRmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
2
of which in humans
3
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
2